Little is known about the mechanisms and the kinetics of the so-called graft-versus-leukemia
(GVL) response induced by donor lymphocyte infusions (DLI) in patients with leukemic …

Donor leukocyte infusion (DLI) provides direct and potent graft-versus-leukemia (GVL)
activity to treat relapse after allogeneic stem-cell transplantation. DLI is dramatically effective …

Purpose We retrospectively evaluated the feasibility and safety of a modified prophylactic
donor lymphocytes infusion (DLI) approach in advanced leukemia. Materials and methods …

Four patients with acute myeloid leukaemia relapsed within 6 months of allogeneic BMT.
Three patients were treated with cytosine arabinoside and amsacrine while the fourth …

In this study, we tested the efficacy and safety of donor lymphocyte infusion (DLI) with
granulocyte colony-stimulating factor (G-CSF) priming in patients who relapsed after …

Donor leukocyte infusions (DLI) can reverse relapse of hematologic malignancy following
allogeneic hematopoietic stem cell transplant (HSCT) in some cases. Little is known …

Donor lymphocyte infusions (DLI) are an effective treatment for patients with chronic myeloid
leukemia (CML) in relapse after allografting but the optimal cell dose has yet to be identified …

Donor lymphocyte infusions (DLI) are an effective treatment for relapsed chronic myeloid
leukemia (CML) after allogeneic stem cell transplantation (alloSCT). Leukemia resistance …

Although haploidentical donor lymphocyte infusion (DLI) is a valid treatment option for
relapsed acute myeloid leukemia (AML), the incidence and risk factors for graft-versus-host …

Between 1980 and 1985, 175 patients with acute leukaemia in first or subsequent complete
remission (CR) were treated by chemotherapy or chemoradiotherapy followed by …